Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
EL
Eledon Pharmaceuticals, Inc. Common Stock
ELDN
Mkt Cap
$173.5M
Volume
690.27K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
EL
ELDN
EL
Eledon Pharmaceuticals, Inc. Common Stock
ELDN
News
·
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Mkt Cap
$173.1M
Volume
690.27K
Next Earnings
November 13th
Chart
Financials
Earnings
News
About
Insider
Filings
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Eledon Pharmaceuticals announced updated Phase 2 BESTOW extension study results showing tegoprubart-treated kidney transplant patients maintained significantly higher kidney function (71 vs. 58 mL/min/1.73 m² eGFR at 24 months) compared to tacrolimus, with zero rejections beyond six months versus seven in the tacrolimus arm. The FDA granted Fast Track designation to tegoprubart for kidney transplant rejection prevention, and the company plans to initiate the Phase 3 LEGACY trial in Q4 2026.
GlobeNewswire Inc. · Sep 22, 2026
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Eledon Pharmaceuticals reported positive Phase 2 BESTOW trial results for tegoprubart, demonstrating favorable safety in kidney transplant prevention, and raised $57.5 million in financing to advance transplantation programs.
GlobeNewswire Inc. · Nov 14, 2025
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
Eledon Pharmaceuticals announced positive Phase 2 trial results for tegoprubart, a potential new immunosuppression treatment for kidney transplant patients, showing promising safety and efficacy with reduced side effects compared to tacrolimus.
GlobeNewswire Inc. · Nov 6, 2025
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
Eledon Pharmaceuticals will present topline results from its Phase 2 BESTOW trial evaluating tegoprubart for kidney transplant rejection prevention at the American Society of Nephrology's Kidney Week 2025 in Houston, TX.
GlobeNewswire Inc. · Oct 17, 2025
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
Eledon Pharmaceuticals' CEO will participate in a fireside chat at the Cantor Global Healthcare Conference, discussing the company's investigational product tegoprubart, an anti-CD40L antibody targeting immune-modulating therapies for conditions like kidney transplantation and ALS.
GlobeNewswire Inc. · Aug 29, 2025
Global Renal Transplant Therapeutics Market is Expected to Cross ~USD 18 Billion by 2032 | DelveInsight
The global renal transplant therapeutics market is projected to grow significantly by 2032, driven by increasing kidney disease prevalence, advanced research, and innovative therapies to prevent transplant rejection.
GlobeNewswire Inc. · Aug 6, 2025
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Pharmaceuticals announced that its investigational anti-CD40L antibody, tegoprubart, was used as a key component of the immunosuppression therapy regimen in a patient who recently received a transplanted kidney from a genetically modified pig. The procedure was performed at Massachusetts General Hospital in collaboration with partner eGenesis.
GlobeNewswire Inc. · Feb 7, 2025
4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com
The article discusses four small-cap stocks that offer high risk and high reward potential as investors rotate their portfolios. The stocks are from the biotech and electric vehicle sectors, with analysts seeing significant upside but also inherent risks.
Investing.com · Jul 24, 2024
Are Medical Stocks Lagging DaVita (DVA) This Year?
Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Zacks Investment Research · Jun 26, 2024
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
GlobeNewswire Inc. · Jun 3, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
EL
ELDN
Eledon Pharmaceuticals, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
ELDN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ELDN yet.
Related Tickers
Earnings